Company intelligence / Profile preview

Luciole Pharmaceuticals

Sherborn, Massachusetts, United Statesluciolepharma.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Luciole Pharmaceuticals is developing small molecule activators of OGG1 to enhance mitochondrial DNA repair. Their lead program is in preclinical development, with demonstrated efficacy in cell-based models showing protection against oxidative stress and rescue of loss-of-function variants. The company has received SBIR funding to advance these programs toward neurodegenerative indications such as Alzheimer’s disease.

Therapeutic areas: GastroenterologyNeurologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Partnerships

Cyclica (AI-enabled drug discovery collaboration)

Beyond the preview

Go deeper on Luciole Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Luciole Pharmaceuticals.

Explore the full profile